Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents
Annals of Pharmacotherapy · 2023
DOI: 10.1177/10600280231163252 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, 2023. Verfasst von Haley Raible und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Raabe College of Pharmacy, Ohio Northern University, Ada, OH, USA. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Viloxazine, Central Nervous System Stimulants. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: endowed fellowship, Raabe College of Pharmacy, Ohio Northern University.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objective
To describe the efficacy and safety of extended-release viloxazine (viloxazine ER; Qelbree) for the treatment of attention-deficit hyperactivity disorder (ADHD) in school-age children and adolescents (6-17 years). Data Sources: A literature search was conducted with PubMed using the following terms: viloxazine and ADHD (August 1, 2017 to February 1, 2023). Study Selection and Data Extraction: All relevant English-language articles examining the efficacy and safety of viloxazine ER were considered for inclusion. Data Synthesis: Phase III studies reported significant improvement in ADHD symptoms after viloxazine ER treatment in both school-age children (100 mg/d, P = 0.0004 and 200 mg/d, P < 0.0001; NCT03247530) and adolescents (200 mg/d, P = 0.0232; 400 mg/d, P = 0.0091; NCT03247517) compared with placebo. Common adverse effects associated with viloxazine ER included somnolence, fatigue, irritability, decreased appetite, and headache. Together, the studies demonstrated the efficacy and safety of viloxazine ER in patients with ADHD. Relevance to Patient Care and Clinical Practice in Comparison With Existing Drugs: Viloxazine ER is a serotonin-norepinephrine modulator, which is administered once daily orally. It is classified as a nonstimulant medication, which can be used in patients with ADHD who do not respond to or cannot tolerate stimulant medications. Even though atomoxetine and viloxazine ER have not been directly compared, clinical studies have suggested that viloxazine ER has a faster onset of action (~1-2 weeks) compared with atomoxetine (~4 weeks). Like atomoxetine, viloxazine ER carries a boxed warning for suicidal ideation and/or behavior.
Conclusion
Viloxazine ER is a useful addition to other nonstimulant medications available to treat patients with ADHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Raabe College of Pharmacy, Ohio Northern University, Ada, OH, USA.
- Department of Pharmaceutical and Biomedical Sciences, The Raabe College of Pharmacy, Ohio Northern University, Ada, OH, USA.
ORCID-Profile: Manoranjan S D'Souza
Förderung
- endowed fellowship
- Raabe College of Pharmacy, Ohio Northern University
Zitieren
APA
Raible, H., & D'Souza, M. S. (2023). Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231163252
Vancouver
Raible H, D'Souza MS. Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents. Annals of Pharmacotherapy. 2023. doi:10.1177/10600280231163252
BibTeX
@article{Raible2023,
author = {Raible, Haley and D'Souza, Manoranjan S},
title = {Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents},
journal = {Annals of Pharmacotherapy},
year = {2023},
doi = {10.1177/10600280231163252}
}
EUVIMED